Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
14.51
+1.03 (7.64%)
At close: Apr 8, 2026, 4:00 PM EDT
14.63
+0.12 (0.83%)
After-hours: Apr 8, 2026, 7:44 PM EDT
Relay Therapeutics Revenue
In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth. Relay Therapeutics had revenue of $7.00M in the quarter ending December 31, 2025.
Revenue (ttm)
$15.36M
Revenue Growth
+53.44%
P/S Ratio
168.89
Revenue / Employee
$79,974
Employees
192
Market Cap
2.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Zai Lab | 460.16M |
| IDEAYA Biosciences | 218.71M |
| Soleno Therapeutics | 190.41M |
| Beam Therapeutics | 139.74M |
| Ascentage Pharma Group International | 82.08M |
| Immunome | 6.94M |
| Celldex Therapeutics | 1.55M |
RLAY News
- 6 days ago - Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - GlobeNewsWire
- 23 days ago - Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? - Benzinga
- 23 days ago - Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - GlobeNewsWire
- 5 weeks ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - GlobeNewsWire
- 2 months ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire